Nicholas Jacob Coulter is a pharmacist who is specialized in Oncology in Akron, Ohio. Patients can reach him at 224 W Exchange St Ste 180, Akron or contact him on 330-344-6159. Active license number of Nicholas Jacob Coulter is 03337965 for Oncology in Ohio. Nicholas Jacob Coulter is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Nicholas Jacob Coulter speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Nicholas Jacob Coulter
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Male
Location:
224 W Exchange St Ste 180, Akron, Ohio, 44302-1705
Phone:
330-344-6159
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Nicholas Jacob Coulter are as mentioned below.
NPI Number:
1205415015
NPI Enumeration Date:
07 Apr, 2021
NPI Last Update On:
07 Apr, 2021
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Nicholas Jacob Coulter are as mentioned below.
Specialization
License Number
State
Status
Oncology
03337965
Ohio
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
224 W Exchange St Ste 180, Akron, Ohio
Zip:
44302-1705
Phone Number:
--
Fax Number:
--
Patients can reach Nicholas Jacob Coulter at 224 W Exchange St Ste 180, Akron, Ohio or can call on phone at 330-344-6159.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.